{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06247735",
            "orgStudyIdInfo": {
                "id": "K-808-2.01"
            },
            "organization": {
                "fullName": "Kowa Research Institute, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.",
            "officialTitle": "A Phase 2, Randomized, Placebo-controlled, Parallel Group, Multicenter 12-week Study With a 52-week Extension to Evaluate the Efficacy and Safety of Two Doses of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid and/or Obeticholic Acid Treatment",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-evaluate-the-efficacy-and-safety-of-k-pemafibrate-in-participants-with-primary-biliary-cholangitis-pbc-with-inadequate-response-to-ursodeoxycholic-acid-udca-and-or-obeticholic-acid-oca-treatment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-22",
            "studyFirstSubmitQcDate": "2024-01-30",
            "studyFirstPostDateStruct": {
                "date": "2024-02-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kowa Research Institute, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC."
        },
        "conditionsModule": {
            "conditions": [
                "Primary Biliary Cholangitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo + K-877 (Group A)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo for 12 Weeks followed by K-808 (Dose A) for 52 Weeks",
                    "interventionNames": [
                        "Drug: K-808 (Dose A)",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Placebo + K-877 (Group B)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo for 12 Weeks followed by K-808 (Dose B) for 52 Weeks",
                    "interventionNames": [
                        "Drug: K-808 (Dose B)",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "K-808 Group A",
                    "type": "EXPERIMENTAL",
                    "description": "K-808 (Dose A) for 64 Weeks",
                    "interventionNames": [
                        "Drug: K-808 (Dose A)"
                    ]
                },
                {
                    "label": "K-808 Group B",
                    "type": "EXPERIMENTAL",
                    "description": "K-808 (Dose B) for 64 Weeks",
                    "interventionNames": [
                        "Drug: K-808 (Dose B)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "K-808 (Dose A)",
                    "description": "Administered orally once daily",
                    "armGroupLabels": [
                        "K-808 Group A",
                        "Placebo + K-877 (Group A)"
                    ],
                    "otherNames": [
                        "Pemafibrate"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "K-808 (Dose B)",
                    "description": "Administered orally once daily",
                    "armGroupLabels": [
                        "K-808 Group B",
                        "Placebo + K-877 (Group B)"
                    ],
                    "otherNames": [
                        "Pemafibrate"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered orally once daily",
                    "armGroupLabels": [
                        "Placebo + K-877 (Group A)",
                        "Placebo + K-877 (Group B)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent change from baseline in serum alkaline phosphatase (ALP)",
                    "description": "Two doses of K-808 compared to placebo after 12 weeks of treatment",
                    "timeFrame": "Baseline to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Achievement of normalization of ALP level",
                    "description": "ALP \u22641 \u00d7 upper limit of normal (ULN)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Achievement of target levels of ALP and total bilirubin (TB)",
                    "description": "After two doses of K-808",
                    "timeFrame": "Baseline to Weeks 12 and 64"
                },
                {
                    "measure": "Change from baseline in liver function parameters",
                    "description": "liver function test results including ALP, total and conjugated bilirubin, albumin, international normalized ratio \\[INR\\], \u03b3-GT, ALT, AST, albumin, platelets count",
                    "timeFrame": "Baseline to Weeks 12 and 64"
                },
                {
                    "measure": "Change from baseline in GLOBE risk score",
                    "description": "calculated by GLOBE scoring system which is calculated based on serum values of bilirubin, ALP, albumin and platelet count.",
                    "timeFrame": "Baseline to Weeks 12 and 64"
                },
                {
                    "measure": "Change from baseline in UK-PBC score",
                    "description": "PBC risk score developed by United Kingdom (UK)-PBC Consortium is a scoring system and the calculation is based on laboratory test measurements and upper limits of normal (ULN) for the total bilirubin (BIL12); alanine transaminase or aspartate transaminase (TA12), and alkaline phosphatase (ALP12) after at least 12 months of UDCA, and the laboratory test measurements and lower limits of normal (LLN) for the serum albumin and platelet count in the same timeframe. A high number is indicative of a worse score.",
                    "timeFrame": "Baseline to Weeks 12 and 64"
                },
                {
                    "measure": "Incidence of Treatment Emergent Adverse Events (TEAEs)",
                    "description": "Coded using the most recent version of Medical Dictionary of Regulatory Activities (MedDRA).",
                    "timeFrame": "Baseline to Week 68"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female participant who has a PBC diagnosis as demonstrated by the presence of \u22652 of the following three diagnostic criteria:\n\n  * History of ALP above ULN for at least 6 months\n  * History of positive antimitochondrial antibody (AMA) titer or positive PBC-specific antinuclear antibody (ANA) titer\n  * Historical liver biopsy consistent with PBC\n* Participant has the following qualifying biochemistry value at Screening:\n\n  * ALP \u22651.5 \u00d7 ULN\n* Participant is \u226518 years of age at consent.\n* Participant meets all other eligibility criteria outlined in the Clinical Study Protocol.\n\nExclusion Criteria:\n\n* Participant meets any one of the following criteria at Screening:\n\n  * ALP\\>10 \u00d7 ULN\n  * ALT or AST \\>5 \u00d7 ULN\n  * Hepatitis C treatment within 5 years of Screening, or active hepatitis C as defined by positive hepatitis C antibody with the presence of hepatitis C virus ribonucleic acid; subjects with active hepatitis B (HBV) infection (hepatitis B surface antigen \\[HbsAg\\] positive) will be excluded. A subject with resolved hepatitis A at least 3 months prior to the Screening Visit can be screened.\n  * Primary sclerosing cholangitis and secondary sclerosing cholangitis (eg, due to cholangiolithiasis, ischemia, telangiectasia, vasculitis, infectious diseases)\n  * Alcoholic liver disease\n  * History of definite autoimmune hepatitis or PBC/autoimmune hepatitis overlap, defined as both of the following: 1) IgG \\>2 \u00d7 ULN and/or positive anti-smooth muscle antibodies, 2) liver histology revealing moderate or severe periportal or periseptal inflammation\n  * Nonalcoholic steatohepatitis (NASH)\n  * Gilbert's Syndrome\n  * Alpha-1-antitrypsin deficiency, cystic fibrosis, Wilson's disease, hemochromatosis based on historically established diagnosis\n  * Drug-induced liver injury (DILI) as defined by typical exposure and history\n  * Known condition that involves bile duct obstruction or cholestasis other than PBC, eg, vascular diseases (eg, Budd-Chiari syndrome, sinusoidal obstruction syndrome, congestive hepatopathy), congenital conditions (ductal plate malformations, Caroli syndrome, congenital liver fibrosis), idiopathic ductopenia\n  * Hepatocellular carcinoma\n* Participant meets any other exclusion criteria outlined in the Clinical Study Protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Director, Clinical Operations",
                    "role": "CONTACT",
                    "phone": "919-433-1600",
                    "email": "Clinical@KowaUS.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Shona Pendse, MD, MMSC",
                    "affiliation": "Kowa Pharma Development Co.",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Springfield Clinic",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Illinois",
                    "zip": "62702",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.80172,
                        "lon": -89.64371
                    }
                },
                {
                    "facility": "Teine Keijinkai Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sapporo",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 43.06667,
                        "lon": 141.35
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002761",
                    "term": "Cholangitis"
                },
                {
                    "id": "D000008105",
                    "term": "Liver Cirrhosis, Biliary"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001649",
                    "term": "Bile Duct Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000002780",
                    "term": "Cholestasis, Intrahepatic"
                },
                {
                    "id": "D000002779",
                    "term": "Cholestasis"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6002",
                    "name": "Cholangitis",
                    "asFound": "Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M11105",
                    "name": "Liver Cirrhosis, Biliary",
                    "asFound": "Primary Biliary Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4935",
                    "name": "Bile Duct Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6019",
                    "name": "Cholestasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M6020",
                    "name": "Cholestasis, Intrahepatic",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4683",
                    "name": "Primary Biliary Cholangitis",
                    "asFound": "Primary Biliary Cholangitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17329",
                    "name": "Ursodeoxycholic Acid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}